What is PFE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 170.99B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PFE?

P/E (TTM) is 40.15 and 52-week range is $23.62 to $30.67 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PFE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PFE?

The company profile lists revenue (TTM) near $63.70B, net income (TTM) near $4.33B, EPS (TTM) near $0.76 when available from the market-data feed. Figures are informational and may lag live markets.

Does PFE show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $1.72, yield near 5.63%, ex-dividend date Nov 6, 2026 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Pfizer Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 5.7B shares outstanding, ISIN US7170811035 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Pfizer Inc.

$PFE

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.

Employees

75,000

Website

www.pfizer.com/

IPO

1944-01-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NEW YORK STOCK EXCHANGE, INC.

ISIN

US7170811035

Headquarters

New York City, New York, US

Shares outstanding

5.7B

NAICS sector

Manufacturing

Institutional ownership

69.02%

Browse other companiesFree AI scores and summaries for more stocks